Nawaf M Althibaiti

Nawaf M Althibaiti

Auto-generated profile, based on publicly available information

Nawaf M Althibaiti

Pharmaceutical Sciences Department, College of Pharmacy, Umm Al-Qura University, Makkah, 24381, Saudi Arabia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
STSaeed M Tayeb
Saeed M Tayeb
JAJaser F Alharbi
Jaser F Alharbi
BABushra B Alattas
Bushra B Alattas
DADana M Alotaibi
Dana M Alotaibi
NANawaf M Althibaiti
Nawaf M Althibaiti
SWSaad Mohammednoor Wali
Saad Mohammednoor Wali
Background: Antimicrobial resistance is a growing global concern that compromises the efficacy of antibiotics, particularly due to the misuse and overuse of these agents. Beta-lactam antibiotics, widely used for their broad-spectrum activity, are increasingly threatened by bacterial resistance mechanisms. Recent studies showed that resistant Gram-negative bacteria cause many hospital infections, which makes the search for new treatments very urgent. Objective: This review explores recent advancements in the development of novel beta-lactam antibiotics, including new drug combinations and structural modifications designed to overcome beta-lactamase degradation and effectively target mutated penicillin-binding proteins (PBPs). Literature Review: One of the main resistance mechanisms in Gram-negative bacteria is the production of beta-lactamases, which break the beta-lactam ring and stop the drug from working. New ideas include adding more than one beta-lactam ring in the drug, combining with strong beta-lactamase inhibitors, and making hybrid structures. These strategies have shown promising results in preclinical evaluations. Conclusion: Novel beta-lactam antibiotics demonstrate significant potential in combating resistant bacterial strains. Future directions should emphasize large-scale in vivo validation, the incorporation of novel β-lactamase inhibitors, and the development of advanced drug delivery systems. Integration of these strategies may enhance the clinical applicability of β-lactams and provide sustainable solutions to address the global burden of antimicrobial resistance.